Asian Research Journal of Gynaecology and Obstetrics

The term “In vitro maturation” (IVM) describes the various stages of immature oocyte maturation in culture. The process of in vitro maturation (IVM) involves the collection of immature oocytes from antral follicles using an altered version of in vitro fertilization (IVF), wherein the last steps of meiosis are accomplished through in vitro culture. IVM primarily benefits high-risk patients, such as those with polycystic ovaries (PCO) and polycystic ovarian syndrome (PCOS), by lowering gonadotrophin stimulation in the patient. IVM provides further advantages for maintaining fertility, especially for individuals with oncofertility. Recent advancements in IVM research have led to markedly higher success rates and safety evidence in terms of newborn and developmental outcomes. Pre-maturation techniques and the creation of novel culture media additives have shown promise in recent times to maximize oocyte developmental stages and maturation proficiency. An essential component of later embryonic development, pregnancy, and healthy live births is the source of the immature oocytes. IVM is a successful treatment that has produced thousands of healthy births and considerable results in terms of acceptable pregnancy and implantation rates. These treatments may be beneficial for many kinds of infertile women. IVM treatment in conjunction with mild-stimulation IVF could be a good substitute for the conventional course of care. It’s time to reevaluate the IVM technology and its advancement, even though IVM treatment is currently regarded as experimental. IVM and mild-stimulation IVF could end up being first-line therapy options rather than just alternatives to traditional therapies.